Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
First Investment: 2015
Synthetic DNA is an important emerging tool in clinical medicine, pharmaceuticals, agriculture, and food. Yet research is being held back by traditional DNA synthesis techniques, which can produce only short segments of DNA. Molecular Assemblies has created an evolved polymerase enzyme that can rapidly synthesize ultra-long oligonucleotide chains with 150 or more nucleotide bases. The enzyme also eliminates the time required for purification by weeding out incomplete oligos as it goes.
Explore Companies
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules